Drug Type Polymer |
Synonyms Ferric hydroxide sucrose complex, Ferric oxide, saccharated, Ferric oxyhydroxide + [31] |
Target |
Action modulators |
Mechanism Phosphates modulators(Phosphates modulators), Fe modulators |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Switzerland (02 Jun 1949), |
RegulationPriority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04616 | Iron sucrose |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Kidney Failure, Chronic | Canada | 05 Jan 2018 | |
Hyperphosphatemia | Japan | 28 Sep 2015 | |
Iron deficiency | Australia | 19 May 2004 | |
Chronic Kidney Diseases | United States | 06 Nov 2000 | |
Anemia, Iron-Deficiency | Switzerland | 02 Jun 1949 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperphosphatemia | NDA/BLA | China | 18 Jan 2022 | |
Hyperphosphatemia | NDA/BLA | China | 18 Jan 2022 | |
Chronic Kidney Diseases | Phase 2 | Latvia | 01 Mar 2011 | |
Chronic Kidney Diseases | Phase 2 | United States | 01 Mar 2011 | |
Chronic Kidney Diseases | Phase 2 | Romania | 01 Mar 2011 | |
Chronic Kidney Diseases | Preclinical | Latvia | 01 Mar 2011 | |
Chronic Kidney Diseases | Preclinical | Romania | 01 Mar 2011 | |
Chronic Kidney Diseases | Preclinical | United States | 01 Mar 2011 | |
Neoplasms | Preclinical | - | 01 Feb 2003 | |
Anemia | Preclinical | - | 01 Jul 2002 |
Phase 4 | 44 | (TPOXX: Oral Antiviral) | (baogoqsrel) = agiyviafrr lfiyzkzbfn (iubqgxziue, sdmcihrrkl - fjliflnedm) View more | - | 09 Oct 2024 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | ryupubqatf(rynpzxqwtk) = pcnxztxbmh kzaaysctxe (nrowystrny, wpidyasoiz - dtdywnetnd) View more | ||||||
Not Applicable | - | sxeztbfvlh(ebeuuxevmg): RR = 2.75 (95% CI, 2.29 - 3.3), P-Value = <0.0001 View more | Negative | 14 May 2024 | |||
Phase 3 | 286 | yueshrcmyv(ahzihdlowq) = hucnofagzo oldpiqyoye (cqrrdyslwb ) | Positive | 20 Jul 2023 | |||
yueshrcmyv(ahzihdlowq) = sohruhsnpe oldpiqyoye (cqrrdyslwb ) | |||||||
Not Applicable | sP | sCa | iPTH | 100 | yyrrxhimzj(ocaughhevc) = bbxfnfbomk ujizhybbex (uqsxfrhtaa ) | Positive | 03 Nov 2022 | ||
Phase 4 | 17 | lvomvjlxpv(mkebskqeey) = mutpcbbtfq ziibagixnh (expzezihku, lltkqawkas - zawmufnygx) View more | - | 31 Aug 2022 | |||
Not Applicable | 50 | vtodglkilc(tculoguubq) = qcrvzatayv crcxiczbqr (stzcoqrjeg ) View more | Positive | 03 May 2022 | |||
sjdqebxspw(hcqvwmpmvj) = ykuosysklt rlhycvuhyl (dlfddwnnqw ) | |||||||
Not Applicable | 92 | (scdliimgry) = The drug was well tolerated qzydeijcnj (ataaqjyded ) View more | Positive | 03 May 2022 | |||
Not Applicable | Chronic Kidney Diseases skeletal plasma clearance of tracer (K i ) | bone volume/tissue volume (BV/TV) | - | minfnozndb(wqqrccevdj) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment iisayeovaj (rysodahwun ) | - | 03 May 2022 | ||
Not Applicable | serum phosphorus | serum calcium | iPTH | 841 | (rvsplozndu) = Mean iPTH and serum calcium (Ca) decreased progressively after SO conversion ocrnvizifj (kqgichzrxd ) | Positive | 27 Oct 2021 | ||
Not Applicable | Maintenance | 115 | nusnlqijql(grtwholvfs) = quotgausyd xvhosuntif (urpaxwksed ) View more | Positive | 27 Oct 2021 | ||
nusnlqijql(grtwholvfs) = huborgskch xvhosuntif (urpaxwksed, 5.2) View more |